

General information about company		
Scrip code	500660	
NSE Symbol	GLAXO	
MSEI Symbol	NOTLISTED	
ISIN	INE159A01016	
Name of the entity	GLAXOSMITHKLINE PHARMACEUTICALS LIMITED	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Reporting Quarter Type	Yearly	
Date of Quarter Ending	31-03-2026	
Type of company	Equity	
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes	
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No	NA
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	No	NA
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	No	NA
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	No	NA
Risk management committee	Applicable	
Market Capitalisation as per immediate previous Financial Year	Top 500 listed entities	
Is SCORE ID Available ?	Yes	
SCORE Registration ID	G00098	
Reason For No SCORE ID		
Type of Submission	Original	
Remarks (website dissemination)		
Remarks for Exchange (not for Website Dissemination)		

Annexure I								
Annexure I to be submitted by listed entity on quarterly basis								
I. Composition of Board of Directors								
Disclosure of notes on composition of board of directors explanatory							Textual Information(1)	
Whether the listed entity has a Regular Chairperson							Yes	
Whether Chairperson is related to MD or CEO							No	
Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
1	Ms	Renu Sud Karnad		00008064	Non-Executive - Non Independent Director	Chairperson		03-09-1952
2	Ms	Sunita Maheshwari		01641411	Non-Executive - Independent Director	Not Applicable		02-06-1966
3	Mr	Manu Anand		00396716	Non-Executive - Independent Director	Not Applicable		20-07-1958
4	Mr	Somasundaram Palamadairamaswamy		00356363	Non-Executive - Independent Director	Not Applicable		15-11-1960
5	Mr	Anup Wadhawan		03565167	Non-Executive - Independent Director	Not Applicable		30-06-1961
6	Mr	Bhushan Akshikar		09112346	Executive Director	Not Applicable		14-10-1970
7	Mr	Juby Chandy		09530618	Executive Director	Not Applicable		12-07-1977
8	Mr	Subesh Williams		07786724	Non-Executive - Non Independent Director	Not Applicable		14-05-1962

I. Composition of Board of Directors					
Disqualification of Directors under section 164 of the Companies Act, 2013					
Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status
1	No				Active
2	No				Active
3	No				Active
4	No				Active
5	No				Active
6	No				Active
7	No				Active
8	No				Active

I. Composition of Board of Directors													
Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	No		01-04-2019				5	1	8	2			
2	No		18-05-2020	13-05-2025		70	2	2	1	0			
3	No		16-05-2022	16-05-2022		43	2	2	2	0			
4	No		26-03-2025	26-03-2025		12.05	2	2	3	2			
5	No		26-03-2025	26-03-2025		12.05	3	3	6	3			
6	NA		01-12-2022				1	0	1	0			
7	NA		01-04-2022	01-04-2025	11-03-2026		1	0	0	0	Others		
8	No		07-04-2017				1	0	0	0			

Text Block	
Textual Information(1)	Juby Chandy moved to senior Finance Role in GSK Global and he resigned as Whole-time Director & CFO w.e.f 11th March 2026

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00356363	Somasundaram Palamadairamaswamy	Non-Executive - Independent Director	Chairperson	30-03-2025		
2	00396716	Manu Anand	Non-Executive - Independent Director	Member	16-05-2022		
3	00008064	Renu Sud Karnad	Non-Executive - Non Independent Director	Member	01-04-2019		

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00396716	Manu Anand	Non-Executive - Independent Director	Chairperson	30-03-2025		
2	03565167	Anup Wadhawan	Non-Executive - Independent Director	Member	30-03-2025		
3	00008064	Renu Sud Karnad	Non-Executive - Non Independent Director	Member	01-04-2019		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00008064	Renu Sud Karnad	Non-Executive - Non Independent Director	Chairperson	01-04-2019		
2	09112346	Bhushan Akshikar	Executive Director	Member	01-12-2022		
3	01641411	Sunita Maheshwari	Non-Executive - Independent Director	Member	30-03-2025		

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00356363	Somasundaram Palamadairamaswamy	Non-Executive - Independent Director	Chairperson	30-03-2025		
2	00396716	Manu Anand	Non-Executive - Independent Director	Member	16-05-2022		
3	00008064	Renu Sud Karnad	Non-Executive - Non Independent Director	Member	01-04-2019		

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01641411	Sunita Maheshwari	Non-Executive - Independent Director	Chairperson	18-05-2020		
2	09112346	Bhushan Akshikar	Executive Director	Member	01-12-2022		
3	03565167	Anup Wadhawan	Non-Executive - Independent Director	Member	30-03-2025		

Other Committee						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

Annexure 1								
Annexure 1								
III. Meeting of Board of Directors								
Disclosure of notes on meeting of board of directors explanatory								
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	06-11-2025				Yes	8	8	4
2		09-02-2026	94		Yes	8	8	4
3		02-03-2026	20		Yes	8	8	4

Annexure 1

IV. Meeting of Committees

Disclosure of notes on meeting of committees explanatory										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	06-11-2025				Yes	3	3	2	0
2	Audit Committee	09-02-2026	94			Yes	3	3	2	0
3	Audit Committee	02-03-2026	20			Yes	3	3	2	0
4	Stakeholders Relationship Committee	09-02-2026				Yes	3	3	1	0
5	Nomination and remuneration committee	09-02-2026				Yes	3	3	2	0
6	Nomination and remuneration committee	02-03-2026	20			Yes	3	3	2	0

Annexure 1

IV. Meeting of Committees

Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
7	Corporate Social Responsibility Committee	19-01-2026				Yes	3	3	2	0
8	Risk Management Committee	09-02-2026				Yes	3	3	2	0

Annexure 1

V. Affirmations

Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

Annexure 1		
Sr	Subject	Compliance status
1	Name of signatory	Ajay Nadkarni
2	Designation	Company Secretary and Compliance Officer

Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)				
I. Disclosure on website in terms of LODR Regulation				
Sr				
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
	As per regulation 46(2) of the LODR:			
1.1	Details of business	Yes		https://india-pharma.gsk.com/en-in/
1.2	Memorandum of Association and Articles of Association	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/memorandum-and-articles-of-association/
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		https://india-pharma.gsk.com/en-in/company/board-of-directors-and-india-leadership-team/
2	Terms and conditions of appointment of independent directors	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/
3	Composition of various committees of board of directors	Yes		https://india-pharma.gsk.com/en-in/company/board-of-directors-and-india-leadership-team/#Governance
4	Code of conduct of board of directors and senior management personnel	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/code-of-internal-procedures-and-conduct-for-regulating-monitoring-and-reporting-of-trading-by-insiders/
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/
6	Criteria of making payments to non-executive directors	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/
7	Policy on dealing with related party transactions	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/
8	Policy for determining 'material' subsidiaries	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/
9	Details of familiarization programmes imparted to independent directors	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/
10	Email address for grievance redressal and other relevant details	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/investors-grievances/
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/investors-grievances/
12	Financial results	Yes		https://india-pharma.gsk.com/en-in/investors/quarterly-results/
13	Shareholding pattern	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/shareholding-pattern/
14	Details of agreements entered into with the media companies and/or their associates	NA		

Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)				
I. Disclosure on website in terms of LODR Regulation				
Sr				
	As per regulation 46(2) of the LODR:			
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	Yes		https://india-pharma.gsk.com/en-in/investors/analyst-meets/
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	Yes		https://india-pharma.gsk.com/en-in/investors/analyst-meets/
16	New name and the old name of the listed entity	NA		
17	Advertisements as per regulation 47 (1)	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/newspaper-publication/
18	Credit rating or revision in credit rating obtained	NA		
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes		https://india-pharma.gsk.com/en-in/investors/annual-reports/
20	Secretarial Compliance Report	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/annual-compliance-report/
21	Materiality Policy as per Regulation 30 (4)	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/policies/
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes		https://india-pharma.gsk.com/media/svvbuqbq/notice-21-apr-26a.pdf
23	Disclosures under regulation 30(8)	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/notices/
24	Statements of deviation(s) or variations(s) as specified in regulation 32	NA		
25	Dividend Distribution policy as per Regulation 43A(1)	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/policies/
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes		https://india-pharma.gsk.com/en-in/investors/shareholder-information/annual-return/
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	NA		
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes		https://india-pharma.gsk.com/en-in/investors/
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes		https://india-pharma.gsk.com/en-in/investors/

Annexure II**II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of ‘independence’ and/or ‘eligibility’	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

Annexure II**II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	

Annexure II

II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26	Meeting of Risk Management Committee	21(3A)	Yes	
27	Quorum of Risk Management Committee meeting	21(3B)	Yes	
28	Gap between the meetings of the Risk Management Committee	21(3C)	Yes	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	

Annexure II

II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4), (5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	NA	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	NA	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	

Annexure II

II. Annual Affirmations

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	Yes	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	NA	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	NA	
	Any other information to be provided - Add Notes			

Annexure II		
1	Name of signatory	Ajay Nadkarni
2	Designation	Company Secretary and Compliance Officer

Annexure II		
III. Affirmations		
Sr	Particulars	Compliance status (Yes/No/NA)
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
	Any other information to be provided	

Annexure II		
1	Name of signatory	Ajay Nadkarni
2	Designation	Company Secretary and Compliance Officer

Details of Cyber security incidence		
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter		No
Number of cyber security incidence or breaches or loss of data event occurred during the quarter		
Sr.	Date of the event	Brief details of the event

Signatory Details	
Name of signatory	Ajay Nadkarni
Designation of person	Company Secretary and Compliance Officer
Place	Mumbai
Date	22-04-2026

Investor Grievance Details	
No. of investor complaints pending at the beginning of Quarter	2
No. of investor complaints received during the Quarter	16
No. of investor complaints disposed off during the Quarter	10
No. of investor complaints those remaining unresolved at the end of the Quarter	8

